Cardiovascular disease (CVD) is a serious public health concern whose incidence has been on a rise and is projected by the World Health Organization to be the leading global cause of mortality by 2030. Heart failure (HF) is a complicated syndrome resulting from various CVDs of heterogeneous etiologies and exhibits varying pathophysiology, including activation of inflammatory signaling cascade, apoptosis, fibrotic pathway, and neuro-humoral system, thereby leading to compromised cardiac function. During this process, several biomolecules involved in the onset and progression of HF are released into circulation. These circulating biomolecules could serve as unique biomarkers for the detection of subclinical changes and can be utilized for monitoring disease severity. Hence, it is imperative to identify these biomarkers to devise an early predictive strategy to stop the deterioration of cardiac function caused by these complex cellular events. Furthermore, measurement of multiple biomarkers allows clinicians to divide HF patients into sub-groups for treatment and management based on early health outcomes. The present article provides a comprehensive overview of current omics platform available for discovering biomarkers for HF management. Some of the existing and novel biomarkers for the early detection of HF with special reference to endothelial biology are also discussed.

心血管疾病 (CVD) 是一个严重的公共卫生问题，其发病率一直在上升，世界卫生组织预计到 2030 年将成为全球主要死亡原因。心力衰竭 (HF) 是由各种 CVD 引起的复杂综合征不同的病因，表现出不同的病理生理学，包括炎症信号级联、细胞凋亡、纤维化途径和神经体液系统的激活，从而导致心脏功能受损。在此过程中，一些参与心力衰竭发生和进展的生物分子被释放到循环中。这些循环生物分子可以作为检测亚临床变化的独特生物标志物，并可用于监测疾病严重程度。因此，必须识别这些生物标志物，以制定早期预测策略，以阻止这些复杂的细胞事件引起的心脏功能恶化。此外，多种生物标志物的测量允许临床医生根据早期健康结果将心力衰竭患者分为亚组进行治疗和管理。本文全面概述了当前可用于发现心力衰竭管理生物标志物的组学平台。还讨论了一些用于早期检测心力衰竭的现有和新型生物标志物，特别是内皮生物学。